IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10821110 B1

PDFFull Text
Date of Patent:
Nov. 03, 2020

Filed:

Oct. 16, 2015

Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases

Applicant:

Hyundai Pharm Co., Ltd., Chungcheongnam-do, KR;

Inventors:

Jin Yang, Gyeonggi-do, KR;

Jin Woong Kim, Gyeonggi-do, KR;

Han Kyu Lee, Gyeonggi-do, KR;

Jae Hyun Kim, Gyeonggi-do, KR;

Chang Mo Son, Gyeonggi-do, KR;

Kyu Hwan Lee, Gyeonggi-do, KR;

Hyung-Ho Choi, Gyeonggi-do, KR;

Daehoon Kim, Seoul, KR;

Tae-Young Ha, Gyeonggi-do, KR;

Jaekeol Rhee, Gyeonggi-do, KR;

Assignee:

HYUNDAI PHARM CO., LTD., Chungcheongnam-do, KR;

Attorney:

Harness, Dickey & Pierce, P.L.C.

Primary Examiner:

Kortney L Klinkel

Assistant Examiner:

Tori Strong

Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/132 (2006.01); A61K 31/357 (2006.01); A61K 31/40 (2006.01); A61K 31/4035 (2006.01); A61K 31/44 (2006.01); A61K 31/445 (2006.01); A61K 31/454 (2006.01); A61K 31/47 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 45/06 (2006.01); C07C 59/72 (2006.01); C07D 207/06 (2006.01); C07D 209/44 (2006.01); C07D 211/14 (2006.01); C07D 211/70 (2006.01); C07D 215/06 (2006.01); C07D 295/096 (2006.01); C07D 317/72 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); A61K 31/192 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 9/0019 (2013.01); A61K 9/14 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/192 (2013.01); A61K 31/357 (2013.01); A61K 31/40 (2013.01); A61K 31/4035 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/454 (2013.01); A61K 31/47 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 45/06 (2013.01); C07C 59/72 (2013.01); C07D 207/06 (2013.01); C07D 209/44 (2013.01); C07D 211/14 (2013.01); C07D 211/70 (2013.01); C07D 215/06 (2013.01); C07D 295/096 (2013.01); C07D 317/72 (2013.01); C07D 401/04 (2013.01); C07D 403/04 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPPIV) inhibitor-based, sulfonylurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X.

Find Patent Forward Citations

Loading…